Genagon Therapeutics Ab

Olink Proteomics Ab

Johan Erik Simon Fredriksson

Olof Andries Blokzijl

Klas Martin Lundberg

A therapeutic agent capable of binding to the receptor CLPTM1 at the surface of an immune cell and modulating its activity for use in modulating the activity of the immune system to treat cancer, wherein the therapeutic agent is capable of inhibiting the growth and/or viability of an anti-inflammatory and/or immunosuppressive cell to relieve unwanted or deleterious immunosuppression by eliminating anti-inflammatory and/or immunosuppressive immune cells; and/or the therapeutic agent is capable of stimulating an antigen-presenting immune cell and acts to stimulate antigen-presenting immune cells to activate an anti-cancer immune response.

Therapeutic agents targeting CLPTM1

The invention relates to apolypeptide capable of binding to TGF-&#x3b2; for use in treating or preventing a condition associated with elevated or unwanted levels of TGF-&#x3b2;, wherein said polypeptide is capable of inhibiting the interaction of TGF-&#x3b2; with the receptor CLPTM1.

Therapeutic peptides that target TGF-beta interaction

The present invention provides a plurality of pairs of proximity probes, each pair being capable of binding to a different target analyte, wherein the first and second proximity probes of each pair of probes comprise universal oligonucleotides conjugated to their analyte binding moieties, and hybridised to the universal oligonucleotides are different tag oligonucleotides comprising universal complement domains common to all tag oligonucleotides and unique domains unique to each tag oligonucleotide, as well as methods for their production.

Growing community of inventors

Bromma, Sweden

Johan Erik Simon Fredriksson